HAVCR2 and acute lymphoblastic leukemia: A significant reduction in the TIM-3 serum levels was observed in the B-ALL patients compared to the non-malignant healthy controls (p = 0.0498), as shown in Figure 2A. No significant differences were reported at the protein levels in the serum TIM-3 levels between the newly diagnosed, remission, and relapse/refractory B-ALL groups and non-malignant healthy controls (Figure 2B).